Vanderbilt-Ingram Cancer Center

Smokers and ex-smokers are at higher risk for developing lung cancer, but researchers still don’t know which individuals are most likely to develop the deadly disease. Now, these high-risk individuals who live in the Nashville area are eligible to participate in the Nashville Lung Cancer Screening Trial, a research project to determine which biomarkers could [...]

Combining targeted therapies might be required for maximum anti-tumor activity when treating HER2-positive breast cancers, according to two new studies by Vanderbilt-Ingram Cancer Center (VICC) investigators. The findings, reported in two papers in the Proceedings of the National Academy of Sciences (PNAS), suggest that upregulation of the HER3 receptor limits the effectiveness of two classes [...]

Patients with metastatic melanoma being treated with the new investigational cancer drug PLX4032 are showing strong responses, with an 80 percent anti-tumor response rate among patients whose tumors are positive for the B-RAF (V600E) gene mutation. However, in all too many cases, patients are developing resistance to the drug and their cancer is beginning to [...]